Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the ...

This adjustment represents a significant 40.39% increase in share count, a 0.34% impact on the current portfolio, with a total value of ?4,833,700. The second largest increase was Tecnoglass Inc (NYSE ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...

Pfizer Inc. has announced that Patrizia Cavazzoni, M.D. will rejoin the company as Chief Medical Officer, Executive Vice ...

Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 ...